p16和bcl-2基因蛋白在大肠癌的表达及临床意义  

Expression and clinical significance of p16 and bcl-2 gene in colorectal carcinoma

作　　者：李潮[1] 李静[2] 李舒[2] 

机构地区：[1]锦州医学院附属第一医院病理科,辽宁锦州121000 [2]锦州医学院附属第一医院消化科,辽宁锦州121000

出　　处：《中国实验诊断学》2006年第5期452-454,共3页Chinese Journal of Laboratory Diagnosis

摘　　要：目的探讨p16b、cl-2基因在大肠癌发生、发展中的作用以及临床中的意义。方法运用免疫组化技术检测大肠癌及腺瘤中p16、bcl-2基因蛋白的表达。结果p16基因蛋白阳性表达率在大肠癌及腺瘤中分别为35.90%、77.27%(P<0.01);bcl-2基因蛋白阳性表达率在大肠癌及腺瘤中分别为61.53%、72.72%(P>0.05)。p16与bcl-2基因蛋白表达在大肠癌中有相关关系,并与肿瘤分化程度、浆膜侵润、淋巴结转移有明显相关性,与年龄、性别、Dukes分期无相关性。结论p16基因的失活与bcl-2基因的过表达在大肠癌的发生、发展中起重要作用;大肠腺瘤是一种重要的癌前病变;对大肠癌及腺瘤进行p16、bcl-2基因检测有助于大肠癌的早期诊断及预后评估。Objective To investigate the important role of P16 and Bcl-2 Gene during the progress of originating and developing of colorectal carcinoma and the clinical significace. Methods Applying standard S-P techniques to detecte P16 and bcl-2 protein expression in colorectal adenoma and carcinoma. Results The positive rates of p16 in colorectal adenoma and carcinoma were 35.90%, 77.27 %, the positive rates of bcl-2 in colorectal adenoma and carcinoma were 61.53 %, 72.72 %, the positive rotes of p16 had significant difference between colorectal adenoma and carcinoma（ P 〈 0.01 ）, the positive rates of bcl-2 had no significant difference between colorectal adenoma and carcinoma（ P 〉 0.05）. There was significant correlation between the positive expression of p16 and bcl-2 gene protein in colorectal carcinoma, the positive rates of p16 and bcl-2 expression were significantly different in different pathological grading, invasion depth and lymphnode metastasis and were no significantly different in age, sex, and stages of Dukes. Conclusion The inactivation of p16 gene and over expressed of bcl-2 gene play an important role in the progress of carcinogenesis of colorectal carcinoma. The adenoma is important precancerous lesions. Detecting the expression of p16 and bcl-2 gene protein in colorectal adenoma and carcinoma could improve the early diagnosis of colorectal carcinoma and evaluate the prognosis.

关 键 词：大肠癌 腺瘤 P16 BCL-2 免疫组化法 

分 类 号：R735.34[医药卫生—肿瘤]